Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Michael J. Mauro, MD, Vivian G. Oehler, MD, James E. Thompson, MD, James K. McCloskey, MD, Michael C. Heinrich, MD, Shaker R. Dakhil, MD, Irene DeGutis, PharmD, David Tabano, PhD, Wasiulla Khan, PhD, Javid J. Moslehi, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137613

Published: 2020

Journal Articles

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Blood (2020) 136 (Supplement 1): 47–50.

https://doi.org/10.1182/blood-2020-139677

Published: 2020

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Oliver G. Ottmann, MD, Giuliana Alimena, Daniel J. DeAngelo, MD PhD, Yeow-Tee Goh, MBBS, MMed, Michael C. Heinrich, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francois-Xavier Mahon, MD PhD Professor, Michael J. Mauro, MD, Hironobu Minami, MD D.MDSci., Marie Huong Nguyen, MD, Delphine Rea, Juan Luis Steegmann, MD, Arkendu Chatterjee, Varsha Iyer, Noelia Martinez, Gary J. Vanasse, MD, Kim Dong-Wook, MD PhD

Blood (2015) 126 (23): 138.

https://doi.org/10.1182/blood.V126.23.138.138

Published: 2015

Journal Articles

Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update

Michael J. Mauro, MD, Shaker Dakhil, MD FACP, Jorge E. Cortes, MD, David A. Rizzieri, MD, Christopher H Keir, MD, Sandy Yi, MS, Michael C. Heinrich, MD, Stuart L. Goldberg, MD, Rosalind Catchatourian, MD, Philip Kuriakose, MD, Jerald P Radich, MD

Blood (2014) 124 (21): 1796.

https://doi.org/10.1182/blood.V124.21.1796.1796

Published: 2014

Journal Articles

Combination Therapy In Mast Cell Neoplasms: Co-Targeting KIT and NFAT Signaling Pathways

Alison Macleod, Janice Patterson, Carol Beadling, PhD, Diana Griffith, Ajia Town, Arin McKinley, Michael C. Heinrich, MD

Blood (2013) 122 (21): 4105.

https://doi.org/10.1182/blood.V122.21.4105.4105

Published: 2013

Journal Articles

Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia.

Marcus M Schittenhelm, Dr., MD, Hartmut Doehner, MD, PhD, Konstanze Doehner, Lothar Kanz, MD, Michael C. Heinrich, MD, Kerstin M Kampa-Schittenhelm, Dr., MD

Blood (2012) 120 (21): 2474.

https://doi.org/10.1182/blood.V120.21.2474.2474

Published: 2012

Journal Articles

AC220, a Potent Second Generation Class I/III Tyrosine Kinase Inhibitor, Displays a Distinct Inhibition Profile on Mutant-FLT3 as Well as -KIT Isoforms

Kerstin M Kampa-Schittenhelm, MD, Mohit Trikha, Richard F. Schlenk, MD, Hartmut Doehner, MD, Konstanze Doehner, MD, Michael C. Heinrich, MD, Marcus Schittenhelm, MD

Blood (2010) 116 (21): 291.

https://doi.org/10.1182/blood.V116.21.291.291

Published: 2010

Journal Articles

FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.

Kerstin M Kampa, MD, Sandra Mueller, PhD, Katharina-Henriette Rasp, Lothar Kanz, MD, Michael C Heinrich, MD, Marcus M Schittenhelm, MD

Blood (2009) 114 (22): 1740.

https://doi.org/10.1182/blood.V114.22.1740.1740

Published: 2009

Journal Articles

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

Kerstin M Kampa, MD, Tanja Grandl, Sandra Mueller, Emmanuel Normant, PhD, Michael Walter, PhD, Wolfgang Schuetz, PhD, Lothar Kanz, MD, Michael C Heinrich, MD, Marcus M Schittenhelm, MD

Blood (2009) 114 (22): 2753.

https://doi.org/10.1182/blood.V114.22.2753.2753

Published: 2009

Journal Articles

Tyrosine Kinase Inhibitors Only Partially Inhibit AKT-Dependent Signaling in Cells Expressing Oncogenic KIT, FLT3 or ABL Kinases. A Potential Model for Leukemia Cell Resistance to TKIs.

Marcus M. Schittenhelm, MD, Kerstin M. Kampa, MD, Sharon Shiraga, Lothar Kanz, MD, PhD, Michael C. Heinrich, MD, PhD

Blood (2007) 110 (11): 2370.

https://doi.org/10.1182/blood.V110.11.2370.2370

Published: 2007

Journal Articles

An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia.

Anupriya Agarwal, PhD, Christopher A. Eide, BA, Amy Harlow, Jeffrey W. Tyner, PhD, Michael J. Mauro, MD, Christopher L. Corless, MD, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2007) 110 (11): 1006.

https://doi.org/10.1182/blood.V110.11.1006.1006

Published: 2007

Journal Articles

Iv Vitro Modeling of the Use of FLT3 Inhibitors To Reduce Chemotherapy Doses for Elderly Patients with AML.

Marcus M. Schittenhelm, MD, Kerstin M. Kampa, MD, Kevin W.H. Yee, MD, Lothar Kanz, MD,PhD, Michael C. Heinrich, MD,PhD

Blood (2007) 110 (11): 4213.

https://doi.org/10.1182/blood.V110.11.4213.4213

Published: 2007

Journal Articles

A Novel, High-Throughput Assay for Detection of ABL T315I Mutations.

Michael C. Heinrich, MD, Jason R. Morich, Emmanuel J. Beillard, Ph.D., Courtney Fuller, Chad D. Galderisi, D.O., Brian J. Druker, M.D.

Blood (2006) 108 (11): 2334.

https://doi.org/10.1182/blood.V108.11.2334.2334

Published: 2006

Journal Articles

In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.

Daniel W. Sherbenou, Matthew J. Wong, Adil Humayun, Laura S. McGreevey, Rui Yang, MD, Michael C. Heinrich, MD, Richard D. Press, MD, PhD, Brian J. Druker, MD, Michael W. Deininger, MD, PhD

Blood (2005) 106 (11): 434.

https://doi.org/10.1182/blood.V106.11.434.434

Published: 2005

Journal Articles

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

Marcus M. Schittenhelm, MD, Sharon Shiraga, Arin Schroeder, Amie S. Corbin, Diana Griffith, Francis Y. Lee, PhD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD, Michael C. Heinrich, MD

Blood (2005) 106 (11): 3358.

https://doi.org/10.1182/blood.V106.11.3358.3358

Published: 2005

Journal Articles

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Lucy C. Crossman, MD, Thomas O’Hare, PhD, Thoralf Lange, MD, Stephanie G. Willis, Eric P. Stoffregen, Amie S. Corbin, Stephen G. O’Brien, MD, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD, Peter G. Middleton, PhD, Michael W.N. Deininger, MD, PhD

Blood (2005) 106 (11): 1530.

https://doi.org/10.1182/blood.V106.11.1530.1530

Published: 2005

Journal Articles

In-Vitro Cytotoxicity of Tipifarnib (Zarnestra TM) in Pediatric AML and ALL Samples Is Independent of RAS Mutations.

Bianca F. Goemans, MD, Christian M. Zwaan, MD, PhD, Gertjan J.L. Kaspers, MD, PhD, Karel Hählen, MD, Dirk Reinhardt, MD, PhD, Ursula Creutzig, MD, PhD, Michael C. Heinrich, MD

Blood (2004) 104 (11): 1172.

https://doi.org/10.1182/blood.V104.11.1172.1172

Published: 2004

Journal Articles

Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.

Daniel J. De Angelo, MD,PhD, Richard M. Stone, MD, Mark L. Heaney, MD,PhD, Stephen D. Nimer, MD, Ronald Paquette, MD, Rebecca Bruner-Klisovic, MD, Michael A. Caligiuri, MD, Michael R. Cooper, MD, Jean-Michel LeCerf, PhD, Ganesh Iyer, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD

Blood (2004) 104 (11): 1792.

https://doi.org/10.1182/blood.V104.11.1792.1792

Published: 2004

NARROW

Cardiovascular and Metabolic Risk in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving First-Line BCR-ABL1 Tyrosine Kinase Inhibitors in the United States: Baseline and Six-Month Follow-up Results from a Prospective Real-World Observational Study

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update

Combination Therapy In Mast Cell Neoplasms: Co-Targeting KIT and NFAT Signaling Pathways

Efficacy Analysis of the Novel Dual PI3K-MTORC1/2 Inhibitors NVP-BGT226 and NVP-BEZ235 in Acute Leukemia.

AC220, a Potent Second Generation Class I/III Tyrosine Kinase Inhibitor, Displays a Distinct Inhibition Profile on Mutant-FLT3 as Well as -KIT Isoforms

FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226.

KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition.

Tyrosine Kinase Inhibitors Only Partially Inhibit AKT-Dependent Signaling in Cells Expressing Oncogenic KIT, FLT3 or ABL Kinases. A Potential Model for Leukemia Cell Resistance to TKIs.

An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia.

Iv Vitro Modeling of the Use of FLT3 Inhibitors To Reduce Chemotherapy Doses for Elderly Patients with AML.

A Novel, High-Throughput Assay for Detection of ABL T315I Mutations.

In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.

Dasatinib (BMS-354825), a Multi-Targeted Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane and Activation Loop Mutant Kit Isoforms Associated with Human Malignancies.

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

In-Vitro Cytotoxicity of Tipifarnib (Zarnestra TM) in Pediatric AML and ALL Samples Is Independent of RAS Mutations.

Phase II Evaluation of the Tyrosine Kinase Inhibitor MLN518 in Patients with Acute Myeloid Leukemia (AML) Bearing a FLT3 Internal Tandem Duplication (ITD) Mutation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only